ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Core Insights - ADC Therapeutics reported financial results for Q4 and full year 2025, highlighting a net product revenue of approximately $22.3 million for Q4 and $73.6 million for the full year, showing an increase from $16.4 million and $69.3 million in 2024 respectively [1][2] - The company anticipates topline data from the LOTIS-5 Phase 3 trial in Q2 2026, with full results expected by the end of 2026, and potential regulatory approval in mid-2027 [1][2] - Cash and cash equivalents stood at $261.3 million as of December 31, 2025, providing a cash runway expected to last at least into 2028 [1][2] Financial Performance - Q4 2025 net product revenue was $22.3 million, up from $16.4 million in Q4 2024, while full year revenue increased to $73.6 million from $69.3 million [1][2] - R&D expenses decreased to $18.2 million for Q4 2025 from $27.1 million in Q4 2024, and full year R&D expenses were $104.0 million compared to $109.6 million in 2024 [1][2] - The net loss for Q4 2025 was $6.4 million, or $0.04 per share, significantly reduced from a net loss of $30.7 million, or $0.29 per share in Q4 2024 [2][4] Operational Updates - The LOTIS-5 trial is expected to provide topline results in Q2 2026, with a supplemental Biologics License Application (sBLA) submission planned for mid-2027, assuming positive results [1][2] - The LOTIS-7 trial is ongoing, with data expected by the end of 2026, showing an 89.8% overall response rate and a 77.6% complete response rate in preliminary results [1][2] - Ongoing investigator-initiated trials are expected to yield data on ZYNLONTA's efficacy in treating additional B-cell malignancies between late 2026 and mid-2027 [1][2] Strategic Developments - An amendment to the HealthCare Royalty financing agreement was made in February 2026, reducing the change of control payment significantly, which enhances strategic flexibility for the company [2][4] - The company raised $150.8 million through PIPE financing in 2025, strengthening its cash position [2][4] - ADC Therapeutics continues to focus on innovation in antibody drug conjugates, with ZYNLONTA being a key product in its portfolio [1][2]